Literature DB >> 10228288

Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants.

O Tammela1, R Ojala, T Iivainen, V Lautamatti, M L Pokela, M Janas, M Koivisto, S Ikonen.   

Abstract

OBJECTIVE: To evaluate whether a prolonged low-dose course of indomethacin would produce an improved closure rate and have fewer side effects compared with a short standard dosage schedule in the management of patent ductus arteriosus (PDA) in preterm infants. STUDY
DESIGN: Sixty-one infants of gestational ages 24 to 32 weeks with a PDA confirmed with echocardiography were randomized to receive 0.2 to 0.1 to 0.1 mg/kg indomethacin in 24 hours (short course, n = 31) or 0.1 mg/kg every 24 hours 7 times (long course, n = 30). Echocardiography was done 3, 9, and 14 days after the treatment was started, and side effects were monitored.
RESULTS: Primary PDA closure occurred more often in the short course group (94% vs 67%, P =.011), but the sustained closure rates were not different (74% vs 60%). Surgical PDA ligations were less frequent in the short course group than in the long course group. The short course group had a shorter duration of oxygen supplementation, less frequent symptoms of necrotizing enterocolitis, and a lower rate of urea retention. Mortality and other neonatal morbidity rates were similar.
CONCLUSION: A prolonged low-dosage indomethacin regimen offers no advantage compared with a standard-dosage short course in the management of a hemodynamically significant PDA in preterm infants.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10228288     DOI: 10.1016/s0022-3476(99)70239-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  Pharmacologic, pharmacodynamic, and pharmacokinetic considerations with intravenous Ibuprofen lysine.

Authors:  Edmund V Capparelli
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

2.  Renal follow up of premature infants with and without perinatal indomethacin exposure.

Authors:  R Ojala; M Ala-Houhala; S Ahonen; A Harmoinen; V Turjanmaa; S Ikonen; O Tammela
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-01       Impact factor: 5.747

3.  B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants.

Authors:  Joon Sik Kim; Eun Jung Shim
Journal:  Korean Circ J       Date:  2012-03-26       Impact factor: 3.243

Review 4.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

5.  Indomethacin use for the management of patent ductus arteriosus in preterms: a web-based survey of practice attitudes among neonatal fellowship program directors in the United States.

Authors:  S B Amin; C Handley; O Carter-Pokras
Journal:  Pediatr Cardiol       Date:  2007-04-24       Impact factor: 1.655

Review 6.  Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.

Authors:  Souvik Mitra; Ivan D Florez; Maria E Tamayo; Lawrence Mbuagbaw; Thuva Vanniyasingam; Areti Angeliki Veroniki; Adriana M Zea; Yuan Zhang; Behnam Sadeghirad; Lehana Thabane
Journal:  JAMA       Date:  2018-03-27       Impact factor: 56.272

7.  Patent ductus arteriosus in preterm neonates.

Authors:  Ramesh Agarwal; Ashok K Deorari; Vinod K Paul
Journal:  Indian J Pediatr       Date:  2008-03       Impact factor: 1.967

8.  Tubular proteinuria in pre-term and full-term infants.

Authors:  Riitta Ojala; Marja Ala-Houhala; Aimo P T Harmoinen; Tiina Luukkaala; Jukka Uotila; Outi Tammela
Journal:  Pediatr Nephrol       Date:  2005-11-17       Impact factor: 3.714

Review 9.  Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

Review 10.  Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.

Authors:  C Herrera; J Holberton; P Davis
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.